Discover why Gilead Sciences (GILD) is a top healthcare stock in 2025 with strong fundamentals and growth potential.
Shares of Gilead Sciences Inc. rose 4.21% to $122.81 Friday, on what proved to be an all-around great trading session for the ...
Source: ‘Miracle’ HIV shot rollout in Zimbabwe sparks debate – DW – 10/16/2025 Zimbabwe is among 10 nations rolling out ...
Kite has paid $120 million upfront to Pregene to gain certain license rights and to collaborate on developing in vivo cell therapies with the Shenzhen, China-based firm. Pregene is entitled to receive ...
T, this time inking a deal worth up to $1.64 billion biobucks with Chinese biotech Pregene Biopharma. | Gilead’s Kite Pharma is doubling down on in vivo CAR-T, this time inking a deal worth up to ...
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best stocks to buy according to Jim Simons’ Renaissance Technologies. On ...
The partnership is part of Boys & Girls Clubs of America’s ongoing commitment to prepare America’s youth for life and work. As the U.S. faces a projected shortfall of 1.4 million skilled workers by ...
Zacks Investment Research on MSN
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...
At Salesforce’s annual Dreamforce event for customers last year, CEO Marc Benioff told roughly 45,000 attendees that using ...
The biopharma will aim to bolster its pipeline, with plans to present updated results for novel long-acting combination ...
GSK’s ViiV Healthcare and its bimonthly pre-exposure prophylaxis (PrEP) medicine Apretude had to make room for another ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback